StemCell Institute: Report on Corporate Governance June 27, 2024.
StemCell Institute: Interim report
StemCell Institute: Internal Control Report - 25th Period (04/01/2023-03/31/2024)
StemCell Institute: Confirmatory letter.
StemCell Institute: Regarding matters related to dominant shareholders.
StemCell Institute: Matters related to business plans and growth potential.
StemCell Institute: Securities Report - 25th period (April 1, 2023 - March 31, 2024)
StemCell Institute: Independent Company Executives Declaration
StemCell Institute: Notice of the 25th Regular Shareholders' Meeting and Shareholders' Meeting Materials.
StemCell Institute: Notice regarding the year-end dividend forecast for the 2nd quarter (dividend commemorating the 25th anniversary of establishment (first dividend)) for the fiscal year ending March 31, 2025
StemCell Institute: Financial results presentation materials for the fiscal year ending March 2024
StemCell Institute: Summary of financial results for the fiscal year ending March 31, 2024 [Japanese GAAP] (unconsolidated)
StemCell Institute: Extraordinary Report
StemCell Institute: Notice Concerning the Recording of Gains (Extraordinary Profit) from the Sale of Investment Securities
Stemcell Research Institute: Quarterly Report - 25th Quarter 3rd Quarter (2023/10/01 - 2023/12/31)
Stem Cell Laboratory: Confirmation
StemCell Institute: Supplementary explanation of financial results for the 3rd quarter of the fiscal year ending March 31, 2024
StemCell Institute: Summary of financial results for the 3rd quarter of the fiscal year ending March 31, 2024 [Japanese GAAP] (unconsolidated)
StemCell Institute: Notice regarding executive officers, general personnel affairs, and organizational restructuring
StemCell Institute: Notice regarding the selection of loan stocks for our shares
No Data